Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

BACKGROUND: Patients with glioblastoma (GBM) have a poor prognosis and limited effective treatment options. Bevacizumab has been approved for treatment of recurrent GBM, but there is questionable survival benefit. Based on preclinical and early clinical data indicating that CD105 upregulation may re...

Descripción completa

Detalles Bibliográficos
Autores principales: Galanis, Evanthia, Anderson, S Keith, Twohy, Erin, Butowski, Nicholas A, Hormigo, Adilia, Schiff, David, Omuro, Antonio, Jaeckle, Kurt A, Kumar, Shaji, Kaufmann, Timothy J, Geyer, Susan, Kumthekar, Priya U, Campian, Jian, Giannini, Caterina, Buckner, Jan C, Wen, Patrick Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154335/
https://www.ncbi.nlm.nih.gov/pubmed/35664553
http://dx.doi.org/10.1093/noajnl/vdac041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154335/
https://www.ncbi.nlm.nih.gov/pubmed/35664553
http://dx.doi.org/10.1093/noajnl/vdac041

Ejemplares similares